1
|
Satapathi D, Das M, Das UK, Laha S, Kundu P, Choudhuri I, Bhattacharya N, Samanta BC, Chattopadhyay N, Maity T. Experimental and molecular modelling demonstration of effective DNA and protein binding as well as anticancer potential of two mononuclear Cu(II) and Co(II) complexes with isothiocyanate and azide as anionic residues. Int J Biol Macromol 2024; 275:133716. [PMID: 38977049 DOI: 10.1016/j.ijbiomac.2024.133716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2024] [Revised: 07/03/2024] [Accepted: 07/05/2024] [Indexed: 07/10/2024]
Abstract
In the present study, one mononuclear Cu(II) [CuL(SCN)] (1) and one mononuclear Co(II) [CoLN3] (2) complexes, with a Schiff base ligand (HL) formed by condensation of 2-picolylamine and salicylaldehyde, have been successfully developed and structurally characterized. The square planer geometry of both complexes is fulfilled by the coordination of one deprotonated ligand and one ancillary ligand SCN-(1) or N3-(2) to the metal centre. Binding affinities of both complexes with deoxyribonucleic acid (DNA) and human serum albumin (HSA) are investigated using several biophysical and spectroscopic techniques. High values of the macromolecule-complex binding constants and other results confirm the effectiveness of both complexes towards binding with DNA and HSA. The determined values of the thermodynamic parameters support spontaneous interactions of both complexes with HSA, while fluorescence displacement and DNA melting studies establish groove-binding interactions with DNA for both complexes 1 and 2. The molecular modelling study validates the experimental findings. Both complexes are subjected to an MTT test establishing the anticancer property of complex 1 with lower risk to normal cells, confirmed by the IC50 values of the complex for HeLa cancer cells and HEK normal cells. Finally, a nuclear staining analysis reveals that the complexes have caused apoptotic cell death.
Collapse
Affiliation(s)
- Dibyendu Satapathi
- Department of Chemistry, Prabhat Kumar College, Purba Medinipur, Contai, West Bengal 721404, India
| | - Manik Das
- Department of Chemistry, Prabhat Kumar College, Purba Medinipur, Contai, West Bengal 721404, India
| | - Uttam Kumar Das
- Department of Chemistry, School of Physical Science, Mahatma Gandhi Central University, Bihar, India
| | - Soumik Laha
- Indian Institute of Chemical Biology, Jadavpur, Kolkata, West Bengal, India
| | - Pronab Kundu
- Department of Chemistry, Presidency University, Yelahanka, Bengaluru 560064, India
| | - Indranil Choudhuri
- Department of Biotechnology, Panskura Banamali College, Panskura, West Bengal, India
| | - Nandan Bhattacharya
- Department of Biotechnology, Panskura Banamali College, Panskura, West Bengal, India
| | | | | | - Tithi Maity
- Department of Chemistry, Prabhat Kumar College, Purba Medinipur, Contai, West Bengal 721404, India.
| |
Collapse
|
2
|
Ornelas C, Astruc D. Ferrocene-Based Drugs, Delivery Nanomaterials and Fenton Mechanism: State of the Art, Recent Developments and Prospects. Pharmaceutics 2023; 15:2044. [PMID: 37631259 PMCID: PMC10458437 DOI: 10.3390/pharmaceutics15082044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2023] [Revised: 07/24/2023] [Accepted: 07/26/2023] [Indexed: 08/27/2023] Open
Abstract
Ferrocene has been the most used organometallic moiety introduced in organic and bioinorganic drugs to cure cancers and various other diseases. Following several pioneering studies, two real breakthroughs occurred in 1996 and 1997. In 1996, Jaouen et al. reported ferrocifens, ferrocene analogs of tamoxifen, the chemotherapeutic for hormone-dependent breast cancer. Several ferrocifens are now in preclinical evaluation. Independently, in 1997, ferroquine, an analog of the antimalarial drug chloroquine upon the introduction of a ferrocenyl substituent in the carbon chain, was reported by the Biot-Brocard group and found to be active against both chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum. Ferroquine, in combination with artefenomel, completed phase IIb clinical evaluation in 2019. More than 1000 studies have been published on ferrocenyl-containing pharmacophores against infectious diseases, including parasitic, bacterial, fungal, and viral infections, but the relationship between structure and biological activity has been scarcely demonstrated, unlike for ferrocifens and ferroquines. In a majority of ferrocene-containing drugs, however, the production of reactive oxygen species (ROS), in particular the OH. radical, produced by Fenton catalysis, plays a key role and is scrutinized in this mini-review, together with the supramolecular approach utilizing drug delivery nanosystems, such as micelles, metal-organic frameworks (MOFs), polymers, and dendrimers.
Collapse
Affiliation(s)
- Catia Ornelas
- ChemistryX, R&D Department, R&D and Consulting Company, 9000-160 Funchal, Portugal
| | - Didier Astruc
- University of Bordeaux, ISM, UMR CNRS, No. 5255, 351 Cours de la Libération, CEDEX, 33405 Talence, France
| |
Collapse
|
3
|
NOVEL FERROCENYLBISPHOSPHONATE HYBRID COMPOUNDS: SYNTHESIS, CHARACTERIZATION AND POTENT ACTIVITY AGAINST CANCER CELL LINES. Bioorg Med Chem 2022; 58:116652. [DOI: 10.1016/j.bmc.2022.116652] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2021] [Revised: 12/29/2021] [Accepted: 01/28/2022] [Indexed: 11/19/2022]
|
4
|
The redox mechanism of ferrocene and its phytochemical and biochemical compounds in anticancer therapy: A mini review. INORG CHEM COMMUN 2021. [DOI: 10.1016/j.inoche.2021.109044] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
5
|
Biegański P, Godel M, Riganti C, Kawano DF, Kopecka J, Kowalski K. Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro. Bioorg Chem 2021; 119:105514. [PMID: 34864281 DOI: 10.1016/j.bioorg.2021.105514] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Accepted: 11/21/2021] [Indexed: 01/22/2023]
Abstract
Thanks to development of erlotinib and other target therapy drugs the lung cancer treatment have improved a lot in recent years. However, erlotinib-resistant lung cancer remains an unsolved clinical problem which demands for new therapeutics to be developed. Herein we report the synthesis of a library of 1,4- and 1,5-triazole ferrocenyl derivatives of erlotinib together with their anticancer activity studies against erlotinib-sensitive A549 and H1395 as well as erlotinib-resistant H1650 and H1975 cells. Studies showed that extend of anticancer activity is mainly related to the length of the spacer between the triazole and the ferrocenyl entity. Among the series of investigated compounds two isomers commonly bearing C(O)CH2CH2 spacer have shown superior to erlotinib activity against erlotinib-resistant H1650 and H1975 cells whereas compound with short methylene spacer devoid of any activity. In-depth biological studies for the most active compound showed differences in its mechanism of action in compare to erlotinib. The latter is known EGFR inhibitor whereas their ferrocenyl congener exerts anticancer activity mainly as ROS-inducer which activates mitochondrial pathway of apoptosis in cancer cells. However, docking studies suggested that the most active compound can also binds to the active site of EGFR TK in a similar way as erlotinib.
Collapse
Affiliation(s)
- Przemysław Biegański
- Department of Organic Chemistry, Faculty of Chemistry, University of Łódź, Tamka 12, 91-403 Łódź, Poland.
| | - Martina Godel
- Department of Oncology, University of Torino, via Santena 5/bis, 10126 Turin, Italy.
| | - Chiara Riganti
- Department of Oncology, University of Torino, via Santena 5/bis, 10126 Turin, Italy.
| | - Daniel Fábio Kawano
- Faculty of Pharmaceutical Sciences, University of Campinas - UNICAMP, 200 Cândido Portinari Street, Campinas, SP 13083-871, Brazil.
| | - Joanna Kopecka
- Department of Oncology, University of Torino, via Santena 5/bis, 10126 Turin, Italy.
| | - Konrad Kowalski
- Department of Organic Chemistry, Faculty of Chemistry, University of Łódź, Tamka 12, 91-403 Łódź, Poland.
| |
Collapse
|
6
|
Novel Ferrocene Derivatives Induce Apoptosis through Mitochondria-Dependent and Cell Cycle Arrest via PI3K/Akt/mTOR Signaling Pathway in T Cell Acute Lymphoblastic Leukemia. Cancers (Basel) 2021; 13:cancers13184677. [PMID: 34572904 PMCID: PMC8467123 DOI: 10.3390/cancers13184677] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Revised: 09/03/2021] [Accepted: 09/08/2021] [Indexed: 12/15/2022] Open
Abstract
Simple Summary T cell acute lymphoblastic leukemia (T-ALL) is a malignant hematologic disease that urgently requires efficient therapeutic agents. The aim of this study is to explore the anti-T-ALL activity of novel ferrocene derivatives. It was found that ferrocene derivatives F1–F7 synthesized by our group inhibited the proliferation of several cancer cell lines in vitro. Among them, F1 and F3 displayed potent cytotoxicity against T-ALL cell lines, especially Jurkat cells, with low cytotoxicity for normal cells. Mechanistically, F1 and F3 could induce apoptosis through mitochondria-dependent pathway mediated by ROS, and cell cycle arrest at G0/G1 phase via the PI3K/Akt/mTOR signaling pathway in Jurkat cells. These results suggested that F1 and F3 could be potential candidates for future T-ALL therapy. Abstract T cell acute lymphoblastic leukemia (T-ALL) is one of the most common causes of death in pediatric malignancies. However, the clinical chemotherapy for T-ALL has been limited by numerous side effects, emphasizing that novel anti-T-ALL drugs are urgently needed. Herein, a series of 2-acyl-1-dimethylaminomethyl-ferrocenes for cancer therapy have been evaluated. Among them, F1 and F3 exhibited potent cytotoxicity against T-ALL cell lines, especially Jurkat cells, with low cytotoxicity for normal cells. Further mechanistic studies revealed that F1 and F3 could induce apoptosis in Jurkat cells by destructing mitochondrial membrane, enhancing reactive oxygen species (ROS) generation, decreasing the Bcl-2/Bax ratio, releasing Cytochrome c, and increasing the expression of Cleaved Caspase-9/-3 and Cleaved PARP. Additionally, F1 and F3 could suppress cell proliferation and arrest the cell cycle at G0/G1 phase through the PI3K/Akt/mTOR signaling pathway by down-regulating the expression of CDK6, Cyclin D1, p-Akt, p-GSK-3β, p-mTOR, p-p70 S6K, and up-regulating the expression of P21 and P27, which would also be a possible mechanism. Consequently, ferrocene derivatives F1 and F3 could induce apoptosis through a mitochondria-dependent pathway mediated by ROS, and cell cycle arrest at G0/G1 phase via the PI3K/Akt/mTOR signaling pathway in Jurkat cells. The present study provided fundamental insights into the clinical application of F1 and F3 for the treatment of T-ALL.
Collapse
|
7
|
Patil VM, Masand N, Verma S, Masand V. Chromones: Privileged scaffold in anticancer drug discovery. Chem Biol Drug Des 2021; 98:943-953. [PMID: 34519163 DOI: 10.1111/cbdd.13951] [Citation(s) in RCA: 35] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2021] [Revised: 09/02/2021] [Accepted: 09/06/2021] [Indexed: 12/16/2022]
Abstract
In the design and discovery of anticancer drugs, various natural heterocyclic scaffolds have attracted considerable interest as privileged structures. For rational drug design, some of the natural scaffolds such as chromones have exhibited wide acceptability due to their drug-like properties. Among the approved anticancer drugs, the scaffolds with high selectivity for a small group of closely related targets are of importance. In the development of selective anticancer agents, the natural, as well as synthetic, can generate highly selective compounds toward cancer targets. The present manuscript includes more particularly the development of cancer inhibitors incorporating the chromone scaffold, with a strong emphasis on their molecular interactions in the anticancer mechanism. It also includes the structure-activity relationship studies and related examples of lead optimization.
Collapse
Affiliation(s)
- Vaishali M Patil
- Department of Pharmaceutical Chemistry, KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad, India
| | - Neeraj Masand
- Department of Pharmacy, Lala Lajpat Rai Memorial Medical College, Meerut, Uttar Pradesh, India
| | - Saroj Verma
- Department of Pharmaceutical Chemistry, SGT University, Gurugram, Haryana, India
| | - Vijay Masand
- Department of Chemistry, Vidya Bharati College, Amravati, Maharashtra, India
| |
Collapse
|
8
|
Shao M, Liu X, Sun Y, Dou S, Chen Q, Yuan XA, Tian L, Liu Z. Preparation and the anticancer mechanism of configuration-controlled Fe(II)-Ir(III) heteronuclear metal complexes. Dalton Trans 2021; 49:12599-12609. [PMID: 32857087 DOI: 10.1039/d0dt02408b] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
A series of configuration-controlled Fe(ii)-Ir(iii) heteronuclear metal complexes, including ferrocene and half-sandwich like iridium(iii) complex units, have been designed and prepared. These complexes show better anticancer activity than cisplatin under the same conditions, especially cis-configurational ones. Laser confocal microscopy analysis confirms that the complexes follow a non-energy-dependent cellular uptake mechanism, accumulate in lysosomes (pearson co-localization coefficient: ∼0.7), lead to lysosomal damage, and eventually induce apoptosis. These complexes can reduce the mitochondrial membrane potential, disturb the cell circle, catalyze the oxidation of nicotinamide-adenine dinucleotide (NADH) and increase the levels of intracellular reactive oxygen species (ROS), following an anticancer mechanism of oxidation. In addition, the complexes could bind to serum protein, and transport through it. Above all, the Fe(ii)-Ir(iii) heteronuclear metal complexes hold promise as potential anticancer agents for further study.
Collapse
Affiliation(s)
- Mingxiao Shao
- Institute of Anticancer Agents Development and Theranostic Application, The Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China.
| | - Xicheng Liu
- Institute of Anticancer Agents Development and Theranostic Application, The Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China.
| | - Yiwei Sun
- Institute of Anticancer Agents Development and Theranostic Application, The Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China.
| | - Shuaihua Dou
- Institute of Anticancer Agents Development and Theranostic Application, The Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China.
| | - Qi Chen
- Institute of Anticancer Agents Development and Theranostic Application, The Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China.
| | - Xiang-Ai Yuan
- Institute of Anticancer Agents Development and Theranostic Application, The Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China.
| | - Laijin Tian
- Institute of Anticancer Agents Development and Theranostic Application, The Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China.
| | - Zhe Liu
- Institute of Anticancer Agents Development and Theranostic Application, The Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China.
| |
Collapse
|
9
|
Bouché M, Hognon C, Grandemange S, Monari A, Gros PC. Recent advances in iron-complexes as drug candidates for cancer therapy: reactivity, mechanism of action and metabolites. Dalton Trans 2020; 49:11451-11466. [PMID: 32776052 DOI: 10.1039/d0dt02135k] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
In this perspective, we discuss iron-complexes as drug candidates that are promising alternatives to conventional platinum-based chemotherapies owing to their broad range of reactivities and to the targeting of different biological systems. Breakthroughs in the comprehension of iron complexes' structure-activity relationship contributed to the clarification of their metabolization pathways, sub-cellular localization and influence on iron homeostasis, while enlightening the primary molecular targets of theses likely multi-target metallodrugs. Both the antiproliferative activity and elevated safety index observed among the family of iron complexes showed encouraging results as per their therapeutic potential and selectivity also with the aim of reducing chemotherapy side-effects, and facilitated more pre-clinical investigations. The purpose of this perspective is to summarize the recent advances that contributed in unveiling the intricate relationships between the structural modifications on iron-complexes and their reactivity, cellular trafficking and global mechanisms of action to broaden their use as anticancer drugs and advance to clinical evaluation.
Collapse
Affiliation(s)
- Mathilde Bouché
- Université de Lorraine, CNRS, L2CM UMR 7053, F-54000 Nancy, France.
| | - Cécilia Hognon
- Université de Lorraine, CNRS, LPCT UMR 7019, F-54000 Nancy, France
| | | | - Antonio Monari
- Université de Lorraine, CNRS, LPCT UMR 7019, F-54000 Nancy, France
| | - Philippe C Gros
- Université de Lorraine, CNRS, L2CM UMR 7053, F-54000 Nancy, France.
| |
Collapse
|
10
|
Wang R, Chen H, Yan W, Zheng M, Zhang T, Zhang Y. Ferrocene-containing hybrids as potential anticancer agents: Current developments, mechanisms of action and structure-activity relationships. Eur J Med Chem 2020; 190:112109. [PMID: 32032851 DOI: 10.1016/j.ejmech.2020.112109] [Citation(s) in RCA: 97] [Impact Index Per Article: 24.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2020] [Revised: 01/29/2020] [Accepted: 01/29/2020] [Indexed: 12/11/2022]
Abstract
Cancer is one of the most fatal threatens to human health throughout the world. The major challenges in the control and eradication of cancers are the continuous emergency of drug-resistant cancer and the low specificity of anticancer agents, creating an urgent need to develop novel anticancer agents. Organometallic compounds especially ferrocene derivatives possess remarkable structural and mechanistic diversity, inherent stability towards air, heat and light, low toxicity, low cost, reversible redox, ligand exchange, and catalytic properties, making them promising drug candidates for cancer therapy. Ferrocifen, a ferrocene-phenol hybrid, has demonstrated promising anticancer properties on drug-resistant cancers. Currently, Ferrocifen is in pre-clinical trial against cancers. Obviously, ferrocene moiety is a useful template for the development of novel anticancer agents. This review will provide an overview of ferrocene-containing hybrids with potential application in the treatment of cancers covering articles published between 2010 and 2020. The mechanisms of action, the critical aspects of design and structure-activity relationships are also discussed.
Collapse
Affiliation(s)
- Ruo Wang
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350116, China.
| | - Huahong Chen
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350116, China
| | - Weitao Yan
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350116, China
| | - Mingwen Zheng
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350116, China
| | - Tesen Zhang
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350116, China
| | - Yaohuan Zhang
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350116, China
| |
Collapse
|
11
|
Ge X, Chen S, Liu X, Wang Q, Gao L, Zhao C, Zhang L, Shao M, Yuan XA, Tian L, Liu Z. Ferrocene-Appended Iridium(III) Complexes: Configuration Regulation, Anticancer Application, and Mechanism Research. Inorg Chem 2019; 58:14175-14184. [DOI: 10.1021/acs.inorgchem.9b02227] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Xingxing Ge
- Institute of Anticancer Agents Development and Theranostic Application, Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China
| | - Shujiao Chen
- Institute of Anticancer Agents Development and Theranostic Application, Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China
| | - Xicheng Liu
- Institute of Anticancer Agents Development and Theranostic Application, Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China
| | - Qinghui Wang
- Institute of Anticancer Agents Development and Theranostic Application, Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China
| | - Lijun Gao
- Institute of Anticancer Agents Development and Theranostic Application, Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China
| | - Chengfeng Zhao
- Institute of Anticancer Agents Development and Theranostic Application, Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China
| | - Lei Zhang
- Institute of Anticancer Agents Development and Theranostic Application, Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China
| | - Mingxiao Shao
- Institute of Anticancer Agents Development and Theranostic Application, Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China
| | - Xiang-Ai Yuan
- Institute of Anticancer Agents Development and Theranostic Application, Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China
| | - Laijin Tian
- Institute of Anticancer Agents Development and Theranostic Application, Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China
| | - Zhe Liu
- Institute of Anticancer Agents Development and Theranostic Application, Key Laboratory of Life-Organic Analysis and Key Laboratory of Pharmaceutical Intermediates and Analysis of Natural Medicine, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China
| |
Collapse
|
12
|
Skiba J, Kowalczyk A, Stączek P, Bernaś T, Trzybiński D, Woźniak K, Schatzschneider U, Czerwieniec R, Kowalski K. Luminescent fac-[Re(CO)3(phen)] carboxylato complexes with non-steroidal anti-inflammatory drugs: synthesis and mechanistic insights into the in vitro anticancer activity of fac-[Re(CO)3(phen)(aspirin)]. NEW J CHEM 2019. [DOI: 10.1039/c8nj05494k] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Luminescent fac-[Re(CO)3(phen)(aspirin)]: insights into in vitro anticancer activity and confocal microscopy imaging in HeLa cells.
Collapse
Affiliation(s)
- Joanna Skiba
- Faculty of Chemistry
- Department of Organic Chemistry
- University of Łódź
- 91-403 Łódź
- Poland
| | - Aleksandra Kowalczyk
- Department of Microbial Genetics
- Faculty of Biology and Environmental Protection
- University of Łódź
- 90-237 Łódź
- Poland
| | - Paweł Stączek
- Department of Microbial Genetics
- Faculty of Biology and Environmental Protection
- University of Łódź
- 90-237 Łódź
- Poland
| | - Tytus Bernaś
- Nencki Institute of Experimental Biology
- Polish Academy of Sciences
- 02-093 Warszawa
- Poland
| | - Damian Trzybiński
- Faculty of Chemistry
- Biological and Chemical Research Centre
- University of Warsaw
- 02-089 Warszawa
- Poland
| | - Krzysztof Woźniak
- Faculty of Chemistry
- Biological and Chemical Research Centre
- University of Warsaw
- 02-089 Warszawa
- Poland
| | - Ulrich Schatzschneider
- Institut für Anorganische Chemie
- Julius-Maximilians-Universität Würzburg
- D-97074 Würzburg
- Germany
| | - Rafał Czerwieniec
- Institut für Physikalische und Theoretische Chemie
- Universität Regensburg
- D-93040 Regensburg
- Germany
| | - Konrad Kowalski
- Faculty of Chemistry
- Department of Organic Chemistry
- University of Łódź
- 91-403 Łódź
- Poland
| |
Collapse
|
13
|
Ren SZ, Wang ZC, Zhu D, Zhu XH, Shen FQ, Wu SY, Chen JJ, Xu C, Zhu HL. Design, synthesis and biological evaluation of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy. Eur J Med Chem 2018; 157:909-924. [PMID: 30149323 DOI: 10.1016/j.ejmech.2018.08.048] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Revised: 07/20/2018] [Accepted: 08/17/2018] [Indexed: 12/22/2022]
Abstract
A series of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy were designed, synthesized and biologically evaluated. Among them, compound 7l displayed the most potent inhibitory against COX-2 (IC50 = 0.82 μM) and antiproliferative activities against Hela cells (IC50 = 0.34 μM) compared with Celecoxib (IC50 = 0.38 and 7.91 μM). The further mechanistic studies revealed that 7l could induce apoptosis of Hela cells by mitochondrial depolarization and the antiproliferative activities of 7l were positively correlated with the levels of intracellular NO release in Hela cells. Most notably, 7l could dramatically suppress tumor growth in Hela cells xenografted mouse model. In summary, compound 7l may be promising candidates for cancer therapy.
Collapse
Affiliation(s)
- Shen-Zhen Ren
- State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, PR China
| | - Zhong-Chang Wang
- State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, PR China.
| | - Dan Zhu
- State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, PR China
| | - Xiao-Hua Zhu
- State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, PR China
| | - Fa-Qian Shen
- State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, PR China
| | - Song-Yu Wu
- State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, PR China
| | - Jin-Jin Chen
- State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, PR China
| | - Chen Xu
- State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, PR China.
| | - Hai-Liang Zhu
- State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, PR China.
| |
Collapse
|
14
|
Silva CFM, Batista VF, Pinto DCGA, Silva AMS. Challenges with chromone as a privileged scaffold in drug discovery. Expert Opin Drug Discov 2018; 13:795-798. [PMID: 29985064 DOI: 10.1080/17460441.2018.1494720] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- Carlos F M Silva
- a Department of Chemistry & QOPNA , University of Aveiro , Aveiro , Portugal
| | - Vasco F Batista
- a Department of Chemistry & QOPNA , University of Aveiro , Aveiro , Portugal
| | - Diana C G A Pinto
- a Department of Chemistry & QOPNA , University of Aveiro , Aveiro , Portugal
| | - Artur M S Silva
- a Department of Chemistry & QOPNA , University of Aveiro , Aveiro , Portugal
| |
Collapse
|
15
|
Kowalski K. Recent developments in the chemistry of ferrocenyl secondary natural product conjugates. Coord Chem Rev 2018. [DOI: 10.1016/j.ccr.2018.04.008] [Citation(s) in RCA: 54] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
16
|
Reis J, Gaspar A, Milhazes N, Borges F. Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances. J Med Chem 2017; 60:7941-7957. [PMID: 28537720 DOI: 10.1021/acs.jmedchem.6b01720] [Citation(s) in RCA: 229] [Impact Index Per Article: 32.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The use of privileged structures in drug discovery has proven to be an effective strategy, allowing the generation of innovative hits/leads and successful optimization processes. Chromone is recognized as a privileged structure and a useful template for the design of novel compounds with potential pharmacological interest, particularly in the field of neurodegenerative, inflammatory, and infectious diseases as well as diabetes and cancer. This perspective provides the reader with an update of an earlier article entitled "Chromone: A Valid Scaffold in Medicinal Chemistry" ( Chem. Rev. 2014 , 114 , 4960 - 4992 ) and is mainly focused on chromones of biological interest, including those isolated from natural sources. Moreover, as drug repurposing is becoming an attractive drug discovery approach, recent repurposing studies of chromone-based drugs are also reported.
Collapse
Affiliation(s)
- Joana Reis
- CIQUP/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto , Porto 4169-007, Portugal
| | - Alexandra Gaspar
- CIQUP/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto , Porto 4169-007, Portugal
| | - Nuno Milhazes
- CIQUP/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto , Porto 4169-007, Portugal
| | - Fernanda Borges
- CIQUP/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto , Porto 4169-007, Portugal
| |
Collapse
|
17
|
Kamenova-Nacheva M, Schröder M, Pasheva E, Slavchev I, Dimitrov V, Momekov G, Nikolova R, Shivachev B, Ugrinova I, Dobrikov GM. Synthesis of ferrocenylmethylidene and arylidene substituted camphane based compounds as potential anticancer agents. NEW J CHEM 2017. [DOI: 10.1039/c7nj00619e] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A series of new compounds with a camphane moiety was synthesized, and some of the ferrocene-containing compounds showed promising anticancer activity and selectivity.
Collapse
Affiliation(s)
- Mariana Kamenova-Nacheva
- Institute of Organic Chemistry with Centre of Phytochemistry
- Bulgarian Academy of Sciences
- Sofia 1113
- Bulgaria
| | - Maria Schröder
- Institute of Molecular Biology “Roumen Tsanev”
- Bulgarian Academy of Sciences
- Sofia 1113
- Bulgaria
| | - Evdokia Pasheva
- Institute of Molecular Biology “Roumen Tsanev”
- Bulgarian Academy of Sciences
- Sofia 1113
- Bulgaria
| | - Ivaylo Slavchev
- Institute of Organic Chemistry with Centre of Phytochemistry
- Bulgarian Academy of Sciences
- Sofia 1113
- Bulgaria
| | - Vladimir Dimitrov
- Institute of Organic Chemistry with Centre of Phytochemistry
- Bulgarian Academy of Sciences
- Sofia 1113
- Bulgaria
| | - George Momekov
- Faculty of Pharmacy
- Medical University of Sofia
- Sofia 1000
- Bulgaria
| | - Rosica Nikolova
- Institute of Mineralogy and Crystallography “Acad. Ivan Kostov”
- Bulgarian Academy of Sciences
- Sofia 1113
- Bulgaria
| | - Boris Shivachev
- Institute of Mineralogy and Crystallography “Acad. Ivan Kostov”
- Bulgarian Academy of Sciences
- Sofia 1113
- Bulgaria
| | - Iva Ugrinova
- Institute of Molecular Biology “Roumen Tsanev”
- Bulgarian Academy of Sciences
- Sofia 1113
- Bulgaria
| | - Georgi M. Dobrikov
- Institute of Organic Chemistry with Centre of Phytochemistry
- Bulgarian Academy of Sciences
- Sofia 1113
- Bulgaria
| |
Collapse
|
18
|
Todorović TR, Vukašinović J, Portalone G, Suleiman S, Gligorijević N, Bjelogrlić S, Jovanović K, Radulović S, Anđelković K, Cassar A, Filipović NR, Schembri-Wismayer P. (Chalcogen)semicarbazones and their cobalt complexes differentiate HL-60 myeloid leukaemia cells and are cytotoxic towards tumor cell lines. MEDCHEMCOMM 2016; 8:103-111. [PMID: 30108695 DOI: 10.1039/c6md00501b] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/01/2016] [Accepted: 10/18/2016] [Indexed: 12/18/2022]
Abstract
Cobalt complexes with semi- and thiosemicarbazones of 8-quinolinecarboxaldehyde have been synthesized and characterized by X-ray diffraction analysis. These novel complexes and a previously synthesized cobalt complex with a selenium-based selenosemicarbazone ligand showed myeloid differentiation activity on all trans retinoic acid resistant HL-60 acute myeloid leukaemia cells. They also showed varying levels of cytotoxicity on five human tumor cell lines: cervix carcinoma cells (HeLa), lung adenocarcinoma cells (A549), colorectal adenocarcinoma cells (LS-174), breast carcinoma cells (MDA-MB-361), and chronic myeloid leukaemia (K562) as well as one normal human cell line: fetal lung fibroblast cells (MRC-5). Leukaemia differentiation was most strongly induced by a metal-free oxygen ligand and the selenium ligand, whilst the latter and the cobalt(ii) complex with an oxygen ligand showed the strongest dose-dependent cytotoxic activity. In four out of five investigated tumor cell lines, it was of the same order of magnitude as cisplatin. These best compounds, however, had lower toxicity on non-transformed MRC-5 cells than cisplatin.
Collapse
Affiliation(s)
- Tamara R Todorović
- Faculty of Chemistry , University of Belgrade , Studentski trg 12-16 , 11000 Belgrade , Serbia
| | - Jelena Vukašinović
- Faculty of Chemistry , University of Belgrade , Studentski trg 12-16 , 11000 Belgrade , Serbia
| | - Gustavo Portalone
- Department of Chemistry , Sapienza University of Rome , P.le Aldo Moro 5 , 00185 Rome , Italy
| | - Sherif Suleiman
- Anatomy Department , Faculty of Medicine and Surgery , University of Malta , Malta .
| | - Nevenka Gligorijević
- Institute for Oncology and Radiology of Serbia , Pasterova 14 , 11000 Belgrade , Serbia
| | - Snezana Bjelogrlić
- Institute for Oncology and Radiology of Serbia , Pasterova 14 , 11000 Belgrade , Serbia
| | - Katarina Jovanović
- Institute for Oncology and Radiology of Serbia , Pasterova 14 , 11000 Belgrade , Serbia
| | - Siniša Radulović
- Institute for Oncology and Radiology of Serbia , Pasterova 14 , 11000 Belgrade , Serbia
| | - Katarina Anđelković
- Faculty of Chemistry , University of Belgrade , Studentski trg 12-16 , 11000 Belgrade , Serbia
| | - Analisse Cassar
- Anatomy Department , Faculty of Medicine and Surgery , University of Malta , Malta .
| | - Nenad R Filipović
- Faculty of Agriculture , University of Belgrade , Nemanjina 6 , 11081 Belgrade , Serbia .
| | | |
Collapse
|
19
|
Koceva-Chyła A, Matczak K, Hikisz MP, Durka MK, Kochel MK, Süss-Fink G, Furrer J, Kowalski K. Insights into the in vitro Anticancer Effects of Diruthenium-1. ChemMedChem 2016; 11:2171-2187. [DOI: 10.1002/cmdc.201600315] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2016] [Indexed: 01/22/2023]
Affiliation(s)
- Aneta Koceva-Chyła
- Department of Medical Biophysics; Faculty of Biology and Environmental Protection; University of Łódź; Pomorska St. 141/143 90236 Łódź Poland
| | - Karolina Matczak
- Department of Medical Biophysics; Faculty of Biology and Environmental Protection; University of Łódź; Pomorska St. 141/143 90236 Łódź Poland
| | - Msc. Paweł Hikisz
- Department of Medical Biophysics; Faculty of Biology and Environmental Protection; University of Łódź; Pomorska St. 141/143 90236 Łódź Poland
| | - Msc. Kamil Durka
- Department of Medical Biophysics; Faculty of Biology and Environmental Protection; University of Łódź; Pomorska St. 141/143 90236 Łódź Poland
| | - Msc. Krzysztof Kochel
- Department of Medical Biophysics; Faculty of Biology and Environmental Protection; University of Łódź; Pomorska St. 141/143 90236 Łódź Poland
| | - Georg Süss-Fink
- Institut de Chimie; Université de Neuchâtel; Avenue de Bellevaux 51 2000 Neuchâtel Switzerland
| | - Julien Furrer
- Department für Chemie und Biochemie; Universität Bern; Freiestrasse 3 3012 Bern Switzerland
| | - Konrad Kowalski
- Department of Organic Chemistry; Faculty of Chemistry; University of Łódź; Tamka St. 12 91403 Łódź Poland
| |
Collapse
|
20
|
Munteanu CR, Suntharalingam K. Advances in cobalt complexes as anticancer agents. Dalton Trans 2016; 44:13796-808. [PMID: 26148776 DOI: 10.1039/c5dt02101d] [Citation(s) in RCA: 199] [Impact Index Per Article: 24.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The evolution of resistance to traditional platinum-based anticancer drugs has compelled researchers to investigate the cytostatic properties of alternative transition metal-based compounds. The anticancer potential of cobalt complexes has been extensively studied over the last three decades, and much time has been devoted to understanding their mechanisms of action. This perspective catalogues the development of antiproliferative cobalt complexes, and provides an in depth analysis of their mode of action. Early studies on simple cobalt coordination complexes, Schiff base complexes, and cobalt-carbonyl clusters will be documented. The physiologically relevant redox properties of cobalt will be highlighted and the role this plays in the preparation of hypoxia selective prodrugs and imaging agents will be discussed. The use of cobalt-containing cobalamin as a cancer specific delivery agent for cytotoxins will also be described. The work summarised in this perspective shows that the biochemical and biophysical properties of cobalt-containing compounds can be fine-tuned to produce new generations of anticancer agents with clinically relevant efficacies.
Collapse
|
21
|
Zhou HY, Li M, Qu J, Jing S, Xu H, Zhao JZ, Zhang J, He MF. Effective Antitumor Candidates Based upon Ferrocenylseleno-Dopamine Derivatives: Growth Inhibition by Induction Cell Apoptosis and Antivascular Effects. Organometallics 2016. [DOI: 10.1021/acs.organomet.6b00237] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
| | | | - Jian Qu
- Institute
of Advanced Materials, Nanjing Tech University, Nanjing 210009, People’s Republic of China
| | | | | | - Juan-Zhi Zhao
- Laboratory
of Translational Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, People’s Republic of China
| | - Jian Zhang
- Laboratory
of Translational Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, People’s Republic of China
| | | |
Collapse
|
22
|
Ma C, Liu X, Cheng S, Li Q, Zhang R. A novel 4-fluorobenzenetelluronic trimethyltin ester: synthesis, characterization and in vitro cytotoxicity assessment. NEW J CHEM 2016. [DOI: 10.1039/c6nj00288a] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
A novel 4-fluorobenzenetelluronic trimethyltin ester (Me3Sn)4[p-F-PhTe(μ-O)(OH)O2]2 (1) has been prepared and structurally characterized, and apoptotic cytotoxicity assessments for A549 cells are made.
Collapse
Affiliation(s)
- Chunlin Ma
- School of Chemistry and Chemical Engineering
- Liaocheng University
- Liaocheng 252059
- P. R. China
| | - Xinglong Liu
- School of Chemistry and Chemical Engineering
- Liaocheng University
- Liaocheng 252059
- P. R. China
| | - Shuang Cheng
- School of Chemistry and Chemical Engineering
- Liaocheng University
- Liaocheng 252059
- P. R. China
| | - Qianli Li
- School of Chemistry and Chemical Engineering
- Liaocheng University
- Liaocheng 252059
- P. R. China
| | - Rufen Zhang
- School of Chemistry and Chemical Engineering
- Liaocheng University
- Liaocheng 252059
- P. R. China
| |
Collapse
|
23
|
Hikisz P, Szczupak Ł, Koceva-Chyła A, Guśpiel A, Oehninger L, Ott I, Therrien B, Solecka J, Kowalski K. Anticancer and Antibacterial Activity Studies of Gold(I)-Alkynyl Chromones. Molecules 2015; 20:19699-718. [PMID: 26528965 PMCID: PMC6331995 DOI: 10.3390/molecules201119647] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2015] [Revised: 10/18/2015] [Accepted: 10/23/2015] [Indexed: 12/11/2022] Open
Abstract
Three gold(I) complexes of alkynyl chromones were synthesized and characterized. The single-crystal X-ray structure analysis of a dinuclear compound and of a flavone derivative exhibit a typical d10 gold(I)-alkynyl linear arrangement. All complexes were evaluated as anticancer and antibacterial agents against four human cancer cell lines and four pathogenic bacterial strains. All compounds show antiproliferative activity at lower micromolar range concentrations. Complex 4 showed a broad activity profile, being more active than the reference drug auranofin against HepG2, MCF-7 and CCRF-CEM cancer cells. The cellular uptake into MCF-7 cells of the investigated complexes was measured by atomic absorption spectroscopy (AAS). These measurements showed a positive correlation between an increased cellular gold content and the incubation time of the complexes. Unexpectedly an opposite effect was observed for the most active compound. Biological assays revealed various molecular mechanisms for these compounds, comprising: (i) thioredoxin reductase (TrxR) inhibition, (ii) caspases-9 and -3 activation; (iii) DNA damaging activity and (iv) cell cycle disturbance. The gold(I) complexes were also bactericidal against Gram-positive methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA) bacterial strains, while showing no activity against the Gram-negative Escherichia coli bacterial strain.
Collapse
Affiliation(s)
- Paweł Hikisz
- Department of Thermobiology, Faculty of Biology and Environmental Protection, University of Łódź, Pomorska 141/143, Łódź PL-90236, Poland; (P.H.); (A.K.-C.)
| | - Łukasz Szczupak
- Department of Organic Chemistry, Faculty of Chemistry, University of Łódź, Tamka 12, Łódź PL-91403, Poland;
| | - Aneta Koceva-Chyła
- Department of Thermobiology, Faculty of Biology and Environmental Protection, University of Łódź, Pomorska 141/143, Łódź PL-90236, Poland; (P.H.); (A.K.-C.)
| | - Adam Guśpiel
- Laboratory of Biologically Active Compounds, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, Warsaw PL-00791, Poland; (A.G.); (J.S.)
| | - Luciano Oehninger
- Institute of Medicinal and Pharmaceutical Chemistry, Technische Universität Braunschweig, Beethovenstr. 55, Braunschweig D-38106, Germany; l.oehninger@tu-braunschweig (L.O.); (I.O.)
| | - Ingo Ott
- Institute of Medicinal and Pharmaceutical Chemistry, Technische Universität Braunschweig, Beethovenstr. 55, Braunschweig D-38106, Germany; l.oehninger@tu-braunschweig (L.O.); (I.O.)
| | - Bruno Therrien
- Institute of Chemistry, Faculty of Science, University of Neuchatel, Avenue de Bellevaux 51, Neuchatel CH-2000, Switzerland;
| | - Jolanta Solecka
- Laboratory of Biologically Active Compounds, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, Warsaw PL-00791, Poland; (A.G.); (J.S.)
| | - Konrad Kowalski
- Department of Organic Chemistry, Faculty of Chemistry, University of Łódź, Tamka 12, Łódź PL-91403, Poland;
- Correspondence: ; Tel.: +48-42-635-5759 (ext. 123); Fax: +48-42-665-5258
| |
Collapse
|
24
|
Kowalski K, Szczupak Ł, Bernaś T, Czerwieniec R. Luminescent rhenium(I)–chromone bioconjugate: Synthesis, photophysical properties, and confocal luminescence microscopy investigation. J Organomet Chem 2015. [DOI: 10.1016/j.jorganchem.2015.01.017] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
25
|
Kowalski K, Szczupak Ł, Oehninger L, Ott I, Hikisz P, Koceva-Chyła A, Therrien B. Ferrocenyl derivatives of pterocarpene and coumestan: Synthesis, structure and anticancer activity studies. J Organomet Chem 2014. [DOI: 10.1016/j.jorganchem.2014.08.027] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|